Early and late proarrhythmia from antiarrhythmic drug therapy

@article{Morganroth1992EarlyAL,
  title={Early and late proarrhythmia from antiarrhythmic drug therapy},
  author={Joel Morganroth},
  journal={Cardiovascular Drugs and Therapy},
  year={1992},
  volume={6},
  pages={11-14}
}
  • J. Morganroth
  • Published 1 February 1992
  • Medicine, Biology
  • Cardiovascular Drugs and Therapy
SummaryAntiarrhythmic drug therapy is used with the hope of suppressing arrhythmias and therefore decreasing their associated symptoms or prolonging life. Unfortunately, many antiarrhythmic drugs have the opposite effect of exacerbating or provoking arrhythmias, a phenomenon that is termed proarrhythmia when such an event is specifically due to the drug in use. Early proarrhythmic events (within 30 days of initiation of drug use) have been reasonably well characterized and are predicted by… 

T-wave Right Slope Provides a New Angle in the Prediction of Drug-Induced Ventricular Arrhythmias

The authors identify the QTc interval in lead V3 as a good, but not perfect, discriminator of drug-induced TdP, correctly classifying 79 % of individuals and T-wave right slope in lead I is identified as a complimentary parameter that improves discrimination of susceptible individuals to 88 %.

References

SHOWING 1-10 OF 17 REFERENCES

Risk factors for the development of proarrhythmic events.

  • J. Morganroth
  • Medicine, Biology
    The American journal of cardiology
  • 1987

Quinidine Syncope: Paroxysmal Ventricular Fibrillation Occurring during Treatment of Chronic Atrial Arrhythmias

The purpose of this communication is to focus attention on syncopal attacks occurring during quinidine therapy and apparently related to paroxysms of ventricular flutter or fibrillation.

Prevalence and characteristics of proarrhythmia from moricizine (Ethmozine).

Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide.

Reassessment of Benefit—Risk Ratio and Treatment Algorithms for Antiarrhythmic Drug Therapy After the Cardiac Arrhythmia Suppression Trial

Because the CAST raises serious questions about the concept of treating asymptomatic but “potentially malignant” arrhythmias guided by ambulatory monitoring, the prophylactic use of any of the antiarrhythmic agents must be considered inappropriate and potentially harmful until otherwise established by specific clinical trials.

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

It is concluded that neither encainide nor flecainide should be used in the treatment of patients with asymptomatic or minimally symptomatic ventricular arrhythmia after myocardial infarction, even though these drugs may be effective initially in suppressing ventricular arrhythmia.

Application of a frequency definition of ventricular proarrhythmia.

Beta blockade during and after myocardial infarction: an overview of the randomized trials.